JERUSALEM , May 7, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the three months ended March 31, 2019 and provides a corporate update.  Highlights of the first quarter 2019 and recent weeks include: Announced that the last

JERUSALEM , May 2, 2019 /PRNewswire/  -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that the results from a pharmacokinetics (PK) study of the Accordion Pill™-Carbidopa/Levodopa (AP-CD/LD) 50/500 mg dosed three times per day (TID) was accepted for presentation in

Company on track to report top-line data in July/August time frame JERUSALEM , April 30, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that the last patient has completed their final visit in the Company's pivotal Phase 3 trial (the ACCORDANCE

JERUSALEM , April 1, 2019 /PRNewswire/ --  Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate in the upcoming HC Wainwright Global Life Sciences Conference . HC Wainwright Global Life Sciences Conference Date: April 7-9, 2019

Presenting at 8:00 am Eastern time on March 14, 2019 JERUSALEM , March 13, 2019 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that the Company's presentation time at Barclays Global Healthcare Conference has been changed as follows.

JERUSALEM , Feb. 28, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the following upcoming investment conferences in March.  Cowen 39th Annual Health Care Conference Date: March 11-13, 2019 Company

JERUSALEM , Feb. 27, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the fourth quarter and year ended December 31, 2018 and provides a corporate update.  Highlights of the fourth quarter 2018 and recent weeks include:

AP-CD/LD met primary endpoint of reducing plasma levodopa variability compared to standard oral CD/LD with statistical significance JERUSALEM , Feb. 19, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces the preliminary results from a pharmacokinetic

Pursuing medical cannabinoids for a variety of pain indications JERUSALEM , Jan. 2, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces the dosing of the first patient in a Phase 1 pharmacokinetic (PK) study of AP-THC, its proprietary Accordion

Reviews 2018 progress and provides outlook for 2019 JERUSALEM , Dec. 19, 2018 /PRNewswire/ --    Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Jeffrey A. Meckler , Vice Chairman and Chief Executive Officer of Intec Pharma , has issued a Letter to Shareholders,